On July 12, 2024, coinciding with the 10th anniversary of the Chinese Academy of Medical Sciences Institute of Systems Medicine/Suzhou Institute of Systems Medicine (referred to as “Suzhou Systems Institute”), the 2024 Systems Medicine Forum was successfully held in Suzhou.

During the forum, Baheal Pharma Group, Suzhou Innovation Investment Group Co., Ltd. (referred to as “Su Innovation Investment”), Suzhou Industrial Park Venture Capital Guidance Fund, and Suzhou Systems Institute signed a strategic cooperation agreement. They will jointly fund and establish an industry fund aimed at the life sciences and health sectors, collaboratively facilitating the commercialization of high-quality scientific research results.

The Systems Medicine Forum is a high-end academic event prominently organized by the Suzhou Systems Institute. This year's forum, themed "Cultivating Strategic Scientific and Technological Forces, Jointly Planning the Development of Systems Medicine," brought together academicians from two academies, strategic scientists, and top experts. They gathered to brainstorm on national needs, cutting-edge fields, and industry hotspots, further advancing the development of systems medicine. This effort aims to provide new ideas, strategies, and methods for the prevention and treatment of major diseases and inject new momentum into the development of the biopharmaceutical industry.

The industry fund promoted during the forum focuses on early-stage investment and incubation of biopharmaceutical and medical device projects, with a particular emphasis on the commercialization of research institute achievements and product industrialization. Baheal Pharma  Group’s Baheal Zhongxin Fund will serve as the fund manager, responsible for the management and operation of the fund. Additionally, all parties will actively cooperate in policy provision, result transformation, research and development cooperation, and product commercialization, establishing a market-oriented, deeply integrated innovation system combining industry, academia, and research. This will advance the construction of an innovative biopharmaceutical industry cluster in Suzhou.

Su Innovation Investment, as Suzhou’s municipal state-owned investment platform, has deeply integrated Suzhou's top state-owned scientific and technological innovation fund resources, continuously guiding capital elements to accelerate into the innovation and entrepreneurship field. It has been recognized as the "Best Government Industry Guidance Fund in China." The Suzhou Industrial Park Venture Capital Guidance Fund is a government guidance fund focused on the deep integration of technology and finance and supporting early-stage investments. The signing of this agreement will fully leverage the advantages of government guidance funds to promote the deep matching of industry and innovation elements.

Suzhou Systems Institute, as a national-level medical research institution, has abundant resources for the commercialization of scientific research results. Ma Wei, deputy director of the institute, stated that the establishment of this fund aims to guide financial resources to accelerate their allocation to the field of technological innovation. The institute will integrate its advantageous scientific research capabilities to promote frontier technological innovations and accelerate the transformation and application of original innovation results.

Li Zhen, Vice President of Capital Operations at Baheal Pharma Group, expressed the hope that the industry fund will empower the innovation and industrial chains, accelerating the commercialization of scientific and technological achievements from a capital perspective. Baheal Zhongxin Fund will ensure the operational management of investment projects, promoting the settlement of more high-quality projects in Suzhou, contributing to the development of the biopharmaceutical and health industries at both regional and national levels.

In recent years, Baheal Pharma Group, in its role as an "industrial investor," has focused on three main tracks: innovative drugs, high-end medical devices, and basic research platforms, using its Baheal Zhongxin Fund as a means. The group has been investing in and incubating innovative achievements with first-in-class potential and breakthrough "neck-choking" technologies. Baiyang has established a comprehensive "six-discipline consultation" innovation incubation system, covering market research, patent management, clinical medical services, and financial support, enabling the selection and cultivation of innovative projects with real clinical application value, effectively optimizing medical scenarios through technological innovation.

As a leading early-stage value investor in China's life and health field, Baheal Zhongxin Fund has become a management platform for the biopharmaceutical industry in multiple regions, including Beijing and Qingdao. Adhering to the philosophy of "investing early, investing new, investing long-term," and leveraging the group's extensive industrial resources and innovative ecosystem, the fund promotes the commercialization and clinical application of scientific research results. Within Baheal's innovative ecosystem, several projects have made significant progress in areas such as fully magnetic levitation artificial hearts, medical electron linear accelerators, electromagnetic positioning puncture navigation devices, innovative nuclear medicine drugs, nuclear medicine SPECT/CT, anti-tumor and bone regeneration innovative drugs.

In the future, Baheal Pharma Group will fully utilize its resource advantages and collaborative capabilities in investing and incubating medical innovation results, deepening cooperation with various partners. The group will promote the commercialization of more innovative and industrially promising projects, continuously fostering the prosperity and development of the medical and health industry.